Isobavachalcone ameliorates Alzheimer disease pathology by autophagy-mediated clearance of amyloid beta and inhibition of NLRP3 inflammasome in primary astrocytes and 5x-FAD mice

Background and AimAlzheimer’s disease (AD) progresses with Aβ plaque deposition and neuroinflammation. Given the complexity of AD pathology, single-target therapies have frequently failed in clinical trials. We hypothesized that a multitarget approach could yield better therapeutic outcomes. To this...

Full description

Saved in:
Bibliographic Details
Main Authors: Dilpreet Kour, Parul Khajuria, Kuhu Sharma, Alpa Sharma, Ankita Sharma, Syed Mudassir Ali, Priya Wazir, P. Ramajayan, Sanghapal D. Sawant, Utpal Nandi, Zabeer Ahmed, Ajay Kumar
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1525364/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849343720677179392
author Dilpreet Kour
Dilpreet Kour
Parul Khajuria
Parul Khajuria
Kuhu Sharma
Kuhu Sharma
Alpa Sharma
Alpa Sharma
Ankita Sharma
Ankita Sharma
Syed Mudassir Ali
Priya Wazir
P. Ramajayan
P. Ramajayan
Sanghapal D. Sawant
Sanghapal D. Sawant
Sanghapal D. Sawant
Utpal Nandi
Utpal Nandi
Zabeer Ahmed
Zabeer Ahmed
Ajay Kumar
Ajay Kumar
author_facet Dilpreet Kour
Dilpreet Kour
Parul Khajuria
Parul Khajuria
Kuhu Sharma
Kuhu Sharma
Alpa Sharma
Alpa Sharma
Ankita Sharma
Ankita Sharma
Syed Mudassir Ali
Priya Wazir
P. Ramajayan
P. Ramajayan
Sanghapal D. Sawant
Sanghapal D. Sawant
Sanghapal D. Sawant
Utpal Nandi
Utpal Nandi
Zabeer Ahmed
Zabeer Ahmed
Ajay Kumar
Ajay Kumar
author_sort Dilpreet Kour
collection DOAJ
description Background and AimAlzheimer’s disease (AD) progresses with Aβ plaque deposition and neuroinflammation. Given the complexity of AD pathology, single-target therapies have frequently failed in clinical trials. We hypothesized that a multitarget approach could yield better therapeutic outcomes. To this end, we identified isobavachalcone (IBC), a natural compound with dual pharmacological activity in reducing Aβ plaques and neuroinflammation.Experimental ProcedurePrimary astrocytes were isolated from 3 to 4 days old C57BL/6J mice pups for in-vitro assays, while in-vivo studies were conducted on 5x-FAD mice. Protein alterations were evaluated using ELISA, western blotting, immunocytochemistry, and immunohistochemistry. Behavioral analyses included the radial arm maze, open field, and rotarod tests. Data from all in vitro and in vivo experiments were analyzed by using one-way ANOVA and post-hoc Bonferroni tests.ResultsIn-vitro analyses in astrocytes demonstrated that IBC at 5 and 10 μM concentrations induce AMPK phosphorylation through CAMKK2, promoting autophagy and inhibiting the NLRP3 inflammasome in primary astrocytes. IBC-treated astrocytes exhibited significant clearance of extracellular amyloid beta. Mechanistic studies highlighted autophagy as a key factor in reducing both NLRP3 inflammasome activity and Aβ levels. Two months of treatment of 5x-FAD mice with IBC at 25 and 50 mg/kg significantly improved cognitive functions, as evidenced by enhanced memory and motor performance in behavioral tests. Subsequent brain tissue analysis revealed that IBC upregulated autophagic proteins to reduce the brain’s amyloid beta levels, resulting in decreased expression of neuroinflammation markers.ConclusionIBC effectively ameliorates AD pathology through autophagy-mediated clearance of Aβ and suppressing neuroinflammation in 5x-FAD mice.
format Article
id doaj-art-65fde869de6f4951b3a12932a84c0b2a
institution Kabale University
issn 1663-9812
language English
publishDate 2025-03-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-65fde869de6f4951b3a12932a84c0b2a2025-08-20T03:42:53ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-03-011610.3389/fphar.2025.15253641525364Isobavachalcone ameliorates Alzheimer disease pathology by autophagy-mediated clearance of amyloid beta and inhibition of NLRP3 inflammasome in primary astrocytes and 5x-FAD miceDilpreet Kour0Dilpreet Kour1Parul Khajuria2Parul Khajuria3Kuhu Sharma4Kuhu Sharma5Alpa Sharma6Alpa Sharma7Ankita Sharma8Ankita Sharma9Syed Mudassir Ali10Priya Wazir11P. Ramajayan12P. Ramajayan13Sanghapal D. Sawant14Sanghapal D. Sawant15Sanghapal D. Sawant16Utpal Nandi17Utpal Nandi18Zabeer Ahmed19Zabeer Ahmed20Ajay Kumar21Ajay Kumar22Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, IndiaAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad, IndiaPharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, IndiaAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad, IndiaPharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, IndiaAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad, IndiaAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad, IndiaNatural Products and Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Jammu, IndiaPharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, IndiaAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad, IndiaPharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, IndiaPharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, IndiaPharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, IndiaAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad, IndiaAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad, IndiaNatural Products and Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Jammu, IndiaOrganic Chemsitry Division, CSIR-National Chemical Laboratory, Pune, IndiaPharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, IndiaAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad, IndiaPharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, IndiaAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad, IndiaPharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, IndiaAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad, IndiaBackground and AimAlzheimer’s disease (AD) progresses with Aβ plaque deposition and neuroinflammation. Given the complexity of AD pathology, single-target therapies have frequently failed in clinical trials. We hypothesized that a multitarget approach could yield better therapeutic outcomes. To this end, we identified isobavachalcone (IBC), a natural compound with dual pharmacological activity in reducing Aβ plaques and neuroinflammation.Experimental ProcedurePrimary astrocytes were isolated from 3 to 4 days old C57BL/6J mice pups for in-vitro assays, while in-vivo studies were conducted on 5x-FAD mice. Protein alterations were evaluated using ELISA, western blotting, immunocytochemistry, and immunohistochemistry. Behavioral analyses included the radial arm maze, open field, and rotarod tests. Data from all in vitro and in vivo experiments were analyzed by using one-way ANOVA and post-hoc Bonferroni tests.ResultsIn-vitro analyses in astrocytes demonstrated that IBC at 5 and 10 μM concentrations induce AMPK phosphorylation through CAMKK2, promoting autophagy and inhibiting the NLRP3 inflammasome in primary astrocytes. IBC-treated astrocytes exhibited significant clearance of extracellular amyloid beta. Mechanistic studies highlighted autophagy as a key factor in reducing both NLRP3 inflammasome activity and Aβ levels. Two months of treatment of 5x-FAD mice with IBC at 25 and 50 mg/kg significantly improved cognitive functions, as evidenced by enhanced memory and motor performance in behavioral tests. Subsequent brain tissue analysis revealed that IBC upregulated autophagic proteins to reduce the brain’s amyloid beta levels, resulting in decreased expression of neuroinflammation markers.ConclusionIBC effectively ameliorates AD pathology through autophagy-mediated clearance of Aβ and suppressing neuroinflammation in 5x-FAD mice.https://www.frontiersin.org/articles/10.3389/fphar.2025.1525364/fullAlzheimer diseaseamyloid betaautophagyisobavachalconeneuroinflammationNLRP3 inflammasome
spellingShingle Dilpreet Kour
Dilpreet Kour
Parul Khajuria
Parul Khajuria
Kuhu Sharma
Kuhu Sharma
Alpa Sharma
Alpa Sharma
Ankita Sharma
Ankita Sharma
Syed Mudassir Ali
Priya Wazir
P. Ramajayan
P. Ramajayan
Sanghapal D. Sawant
Sanghapal D. Sawant
Sanghapal D. Sawant
Utpal Nandi
Utpal Nandi
Zabeer Ahmed
Zabeer Ahmed
Ajay Kumar
Ajay Kumar
Isobavachalcone ameliorates Alzheimer disease pathology by autophagy-mediated clearance of amyloid beta and inhibition of NLRP3 inflammasome in primary astrocytes and 5x-FAD mice
Frontiers in Pharmacology
Alzheimer disease
amyloid beta
autophagy
isobavachalcone
neuroinflammation
NLRP3 inflammasome
title Isobavachalcone ameliorates Alzheimer disease pathology by autophagy-mediated clearance of amyloid beta and inhibition of NLRP3 inflammasome in primary astrocytes and 5x-FAD mice
title_full Isobavachalcone ameliorates Alzheimer disease pathology by autophagy-mediated clearance of amyloid beta and inhibition of NLRP3 inflammasome in primary astrocytes and 5x-FAD mice
title_fullStr Isobavachalcone ameliorates Alzheimer disease pathology by autophagy-mediated clearance of amyloid beta and inhibition of NLRP3 inflammasome in primary astrocytes and 5x-FAD mice
title_full_unstemmed Isobavachalcone ameliorates Alzheimer disease pathology by autophagy-mediated clearance of amyloid beta and inhibition of NLRP3 inflammasome in primary astrocytes and 5x-FAD mice
title_short Isobavachalcone ameliorates Alzheimer disease pathology by autophagy-mediated clearance of amyloid beta and inhibition of NLRP3 inflammasome in primary astrocytes and 5x-FAD mice
title_sort isobavachalcone ameliorates alzheimer disease pathology by autophagy mediated clearance of amyloid beta and inhibition of nlrp3 inflammasome in primary astrocytes and 5x fad mice
topic Alzheimer disease
amyloid beta
autophagy
isobavachalcone
neuroinflammation
NLRP3 inflammasome
url https://www.frontiersin.org/articles/10.3389/fphar.2025.1525364/full
work_keys_str_mv AT dilpreetkour isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT dilpreetkour isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT parulkhajuria isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT parulkhajuria isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT kuhusharma isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT kuhusharma isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT alpasharma isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT alpasharma isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT ankitasharma isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT ankitasharma isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT syedmudassirali isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT priyawazir isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT pramajayan isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT pramajayan isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT sanghapaldsawant isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT sanghapaldsawant isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT sanghapaldsawant isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT utpalnandi isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT utpalnandi isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT zabeerahmed isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT zabeerahmed isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT ajaykumar isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice
AT ajaykumar isobavachalconeamelioratesalzheimerdiseasepathologybyautophagymediatedclearanceofamyloidbetaandinhibitionofnlrp3inflammasomeinprimaryastrocytesand5xfadmice